Parkinson's Disease Market
DelveInsight’s ‘Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of Parkinson’s Disease, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Parkinson’s disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Parkinson’s disease symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Parkinson’s disease symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2018–2030
Parkinson’s Disease Understanding and Treatment Algorithm
Parkinson’s Disease Overview
Parkinson’s Disease (PD) is a progressive disorder caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement.
The cause of PD remains unknown, but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with PD also have a first-degree relative with PD.
Parkinson’s Disease Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnoses available in the Parkinson’s disease market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Parkinson’s Disease market report thoroughly understands Parkinson’s disease symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Parkinson’s disease treatment algorithms and treatment guidelines for Parkinson’s disease symptoms in the US, Europe, and Japan.
There is no standard treatment for PD. Treatment for each person with Parkinson’s is based on his or her symptoms. There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take various medications – all at different doses and at different times of day – to manage symptoms. The medications used to treat Parkinson’s disease include levodopa dopamine agonists, MAO-B inhibitors, COMT-Inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. The main goal of these medications is to lessen motor symptoms or the symptoms that affect movement in people with Parkinson’s disease.
Parkinson’s Disease Epidemiology
The Parkinson’s disease symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.
Key Findings
The total prevalent cases of Parkinson’s disease patients in the 7MM are increasing during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Parkinson’s Disease symptoms epidemiology segmented as the total Prevalent cases of Parkinson’s Disease, gender-specific cases of Parkinson’s Disease, age-specific cases of Parkinson’s Disease, prevalent population of Parkinson’s Disease based on the onset, and stage-specific cases of Parkinson’s Disease. The report includes the Prevalent cases scenario of Parkinson’s Disease in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country-wise Parkinson’s Disease Epidemiology
The epidemiology segment also provides the Parkinson’s disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total number of prevalent cases of Parkinson’s Disease-associated in 7MM countries was 2,415,139 in 2020.
Parkinson’s Disease Drug Chapters
The Parkinson’s disease report’s drug chapter segment encloses the detailed analysis of Parkinson’s disease early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the Parkinson’s disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Parkinson’s Disease Emerging Drugs
Tavapadon (CVL-751/PF-06649751): Cerevel Therapeutics
Cerevel Therapeutics is developing the most advanced therapeutic candidate, tavapadon, to treat both early and late-stage PD. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes to balance meaningful motor activity with a favorable tolerability profile.
Of the two dopamine receptor subtypes, D1/D5 receptor subtypes are expressed in a subset of neurons whose function modulates signaling from the thalamus to the cortex. This pathway is known as the direct motor pathway and is responsible for the appropriate initiation of motor activity. D2/D3 receptor subtypes, expressed by a different group of neurons, signal via the indirect motor pathway, which indirectly regulates the signaling from the thalamus to the cortex. This pathway results in the inhibition of motor activity. The balance between these two groups of neurons allows for proper motor control.
P2B001: Pharma Two B
P2B001 is an investigational drug comprised of low doses of two drugs, pramipexole, and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson’s disease. The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each drug. Lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs in an improved formulation that is hoped to be more effective in controlling Parkinson’s disease symptoms and with fewer side effects than each of the drugs taken alone or the currently available commercial drugs taken together. In a previously completed clinical trial, a significant improvement in Parkinson’s disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with a placebo.
Other Products detailed in the report…
Parkinson’s Disease Market Outlook
The report’s Parkinson’s disease market outlook helps to understand the historic, current better, and forecasted Parkinson’s disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Parkinson’s Disease market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.
According to DelveInsight, the Parkinson’s disease market in 7MM is expected to grow steadily during the study period 2018–2030.
Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and non-pharmacologic approaches (such as exercise and physical, occupational, and speech therapies). Approaches such as deep brain stimulation and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremors, worsening symptoms when the medication wears off, and dyskinesia. Levodopa is safe and effective for people with PD, and there is no reliable data that levodopa speeds disease progression or produces damage to brain cells. Levodopa is extremely beneficial to people with PD and can dramatically improve their quality of life. Levodopa is effective throughout the disease course; however, due to disease progression, the dose of levodopa needs to be increased over time.
Key Findings
This section includes a glimpse of the Parkinson’s disease market in 7MM. Parkinson’s disease market size in the seven major markets was USD 2,707.4 million in 2020.
The United States Market Outlook
This section provides the total Parkinson’s disease market size and market size by therapies in the United States.
The United States accounts for the largest market size of Parkinson’s disease compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Parkinson’s disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Parkinson’s disease market size and market size by therapies in Japan are also mentioned.
Parkinson’s Disease Drugs Uptake
This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Parkinson’s disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Parkinson’s Disease Pipeline Development Activities
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Parkinson’s disease key players involved in developing targeted therapeutics.
Major market players include AbbVie, Cerevel Therapeutics, Amneal Pharmaceuticals, and others.
Pipeline Development Activities
The report covers collaborations, acquisition, merger, licensing, and patent details for Parkinson’s disease emerging therapies.
In July 2021, Ipsen announced the signing of a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist.
Under the terms of the agreement, IRLAB will be eligible to receive up to USD 363 million, including an upfront cash payment of USD 28 million and up to USD 335 million in development, regulatory and commercial milestones. IRLAB is also eligible to receive tiered low double-digit royalties on worldwide net sales of mesdopetam. The transaction does not impact Ipsen’s financial guidance for 2021.
Reimbursement Scenario in Parkinson’s disease
Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.
KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Parkinson’s disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Parkinson’s disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Parkinson’s disease Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Parkinson’s disease, explaining its causes, signs and symptoms, physiology, and currently available therapies.
- Comprehensive insight has been provided into the Parkinson’s disease epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of both the current and emerging therapies for Parkinson’s disease is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
- A detailed review of the Parkinson’s disease market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Parkinson’s disease market.
Report Highlights
- In the coming years, the Parkinson’s disease market is set to change due to the rising awareness of the disease, development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs that are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Parkinson’s disease. The launch of emerging therapies will significantly impact the Parkinson’s disease market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Parkinson’s Disease Report Insights
- Patient Population
- Therapeutic Approaches
- Parkinson’s Disease Pipeline Analysis
- Parkinson’s Disease Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Parkinson’s Disease Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Parkinson’s Disease Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Parkinson’s Disease Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions
Market Insights:
- What was the Parkinson’s disease Market share (%) distribution in 2018, and how would it look in 2030?
- What would be the Parkinson’s disease total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
- What are the key findings of the market across 7MM, and which country will have the largest Parkinson’s disease market size during the forecast period (2018–2030)?
- At what CAGR, the Parkinson’s disease market is expected to grow by 7MM during the forecast period (2018–2030)?
- What would be the Parkinson’s disease market outlook across the 7MM during the forecast period (2018–2030)?
- What would be the Parkinson’s disease market growth till 2030, and what will be the resultant market Size in the year 2030?
Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of Parkinson’s disease?
- What is the historical Parkinson’s disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Parkinson’s Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM concerning the patient population about Parkinson’s disease?
- Out of all 7MM countries, which country would have the largest prevalent population of Parkinson’s disease during the forecast period (2018–2030)?
- At what CAGR is the population expected to grow by 7MM during the forecast period (2018–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Parkinson’s disease along with the approved therapy?
- What are the current treatment guidelines for treating Parkinson’s disease in the USA, Europe, and Japan?
- What is the Parkinson’s Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Parkinson’s disease?
- How many therapies are developed by each company for the treatment of Parkinson’s disease?
- How many emerging therapies are in the mid-stage and late stages of development to treat Parkinson’s disease?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Parkinson’s disease therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Parkinson’s disease and its status?
- What key designations have been granted for the emerging therapies for Parkinson’s disease?
- What are the global historical and forecasted markets of Parkinson’s disease?
Reasons to buy
- The report will help develop business strategies by understanding trends shaping and driving the Parkinson’s disease market.
- To understand the future market competition in the Parkinson’s disease market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Parkinson’s disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Parkinson’s disease market.
- To understand the future market competition in the Parkinson’s disease market.
